Market Cap | 132.94M | P/E | - | EPS this Y | 12.40% | Ern Qtrly Grth | - |
Income | -78.63M | Forward P/E | -1.67 | EPS next Y | 7.30% | 50D Avg Chg | -47.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -58.00% |
Dividend | N/A | Price/Book | 0.81 | EPS next 5Y | - | 52W High Chg | -72.00% |
Recommedations | 1.20 | Quick Ratio | 6.30 | Shares Outstanding | 32.35M | 52W Low Chg | 29.00% |
Insider Own | 0.05% | ROA | -29.39% | Shares Float | 16.89M | Beta | - |
Inst Own | 76.67% | ROE | -54.59% | Shares Shorted/Prior | 260.40K/333.18K | Price | 5.59 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 65,759 | Target Price | 21.60 |
Oper. Margin | - | Earnings Date | - | Volume | 118,668 | Change | -5.89% |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Wedbush | Outperform | Mar 7, 24 |
Wedbush | Outperform | Jan 30, 24 |
HC Wainwright & Co. | Buy | Sep 7, 23 |
HC Wainwright & Co. | Buy | Aug 9, 23 |
Stifel | Buy | Jun 14, 23 |
Wedbush | Outperform | Jun 14, 23 |
Wedbush | Outperform | May 31, 23 |
HC Wainwright & Co. | Buy | May 12, 23 |
HC Wainwright & Co. | Buy | Apr 3, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
McArthur James G | President and CEO President and CEO | Nov 30 | Buy | 4.165 | 1,694 | 7,056 | 1,694 | 12/05/23 |
McArthur James G | President and CEO President and CEO | Jun 08 | Sell | 16.04 | 2,381 | 38,191 | 06/09/23 | |
McArthur James G | President and CEO President and CEO | Jun 08 | Option | 2.71 | 2,381 | 6,453 | 2,381 | 06/09/23 |
Goyal Jaya | EVP, Res. & Preclin... EVP, Res. & Preclin. Dev. | Mar 24 | Sell | 20 | 392 | 7,840 | 03/28/23 | |
Goyal Jaya | EVP, Res. & Preclin... EVP, Res. & Preclin. Dev. | Mar 24 | Option | 10.88 | 392 | 4,265 | 392 | 03/28/23 |
Goyal Jaya | EVP, Res. & Preclin... EVP, Res. & Preclin. Dev. | Feb 06 | Sell | 17.07 | 6,000 | 102,420 | 02/08/23 | |
Goyal Jaya | EVP, Res. & Preclin... EVP, Res. & Preclin. Dev. | Feb 06 | Option | 10.88 | 6,000 | 65,280 | 644 | 02/08/23 |
KEATING LAURIE | Director Director | May 06 | Buy | 12.00 | 4,166 | 49,992 | 4,166 | 01/19/23 |